Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking strategy to diabetes management. These innovative medications function by mimicking the natural actions of GLP-1, a hormone secreted by the gut in response to meals. By activating GLP-1 receptors in the pancreas, these compounds increase insulin release and reduce gluca… Read More

Retaglutide and tirzepatide represent a novel class of medications known as dual GLP-1 and GIP agonists. These agents influence both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that play a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones are o… Read More